1. Home
  2. Pharmaceuticals and Healthcare
  3. Pompe Disease Market - By Type (Late-Onset Pompe Disease, Cl...
Category : Pharmaceuticals and Healthcare
Envisage report cover

Pompe Disease Market - By Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic infantile-onset Pompe Disease) By Therapy (Enzyme Replacement Therapy, Gene Therapy, Others) By End User (Hospitals and Clinics, Research and Academic Institutes) By Region (North America, Europe, Asia Pacific, Middle East & Africa, RoW) - Industry Analysis, Opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 193

Status: Published

Report Code: ARI100709

Global Pompe Disease Market was valued at 1241.24 million and is expected to register a CAGR of 3% during the forecast period of 2020 to 2027 and reach USD 1450 million in 2027. Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies in the mutation of a gene responsible for production of the enzyme acid alpha-glycosidase. This enzyme breaks glycogen into simpler form i.e., glucose but a mutation in the GAA gene prevents this activity. The stoppage of glycogen breakdown causes massive cellular dysfunction, with the marked involvement of the cardiac, smooth, and skeletal muscle.

Pompes disease is categorized on the basis of disease severity, disease progression and age, such as infantile-onset, non-classic infantile-onset and late onset. Within few months of birth, the infantile onset of Pompes disease starts showing its symptoms such as enlarged liver(hepatomegaly), muscle weakness(myopathy), heart defect, and poor muscle tone (hypotony). The infants affected with this disease face challenges of weight gain as well as hampered growth and breathing problems. The affected infant may have large protruding tongue. If untreated, the infant may die of heart failure in the first year of life itself. Non-Classic infantile-onset is usually seen at the age of 1 year. The disease symptoms include poor motor skills and a delayed muscle progress. They may show signs of hearing impairment and abnormally large heart. The muscle weakness may seriously lead to breathing problems. The Late-onset marks its symptoms by later stages of childhood, adolescent age or in adulthood. This form of late onset is a bit milder than the previous ones and doesn’t involve heart. The muscle weakness is generally observed in the legs, trunk and breathing muscles. The progress of the disorder in the muscles controlling breathing will ultimately lead to the respiratory failure.

The Prominent Players in the Global Pompe Disease Treatment Market are Amicus Therapeutics, Inc (US) Sanofi (France), Audentes Therapeutics (US), Oxyrane (UK), Valerion Therapeutics (US), AVROBIO, Inc. (US), CENTOGENE AG (UK).

Analyst Commentary

Pompes disease can occur in various age groups and population across the world. The occurrence of the disease is 1 in 40,000 births in the U.S. In many cases, the people suffering from Pompes Disease in late onset of the disease remain undiagnosed. The symptoms of Pompes Disease are observed due to the complete or partial deficiency of the GAA enzyme. Diagnosis of Pompe disease can be performed by GAA activity assay. Following are the tests for the detection of Pompe disease:

• Sequencing of the GAA gene
• GAA activity assay in blood, cultured amniocytes, chorionic villi and cultured skin fibroblasts.
• The marker, urinary hexose tetrasaccharide can be used to keep a track of patients suffering from Pompe disease
• Cross Reactive Immunological Material (CRIM) analysis

Pompe disease can be treated by symptomatic, supportive and disease-specific ways. As the disease involves impairment of cardiac, respiratory and muscular systems, the treatment necessitates requirement of specialists with expertise in all these disorders. Cardiologists, dieticians, pediatricians, orthopedists may need to co-ordinate and design a well collaborated treatment plan for the patient. The US Food and Drug Administration have approved an enzyme replacement therapy Myozyme for the infantile onset of Pompe disease suffering patients of less than 8 years old. Whereas Lumizyme is used for patients older than 8 years of age. The genetically engineered human GAA enzyme is administered intravenously every two weeks.

Segmentation

The Global Pompe Disease Treatment Market has been divided based on Type, Therapy, and End User.
• The market, based on type, has been segregated into late-onset Pompe disease, classic infantile-onset Pompe disease, and non-classic infantile-onset Pompe disease. The operational CRM segment accounted for the largest market share of 56.4% in 2018, owing to advantages over the other types of Pompe disease treatment.

• On the basis of therapy, the Pompe disease treatment market is bifurcated into enzyme replacement therapy (ERT), gene therapy, and others. The enzyme replacement therapy segment accounted for the largest market share with a value of USD 835.4 million in 2018. This largest share can be attributed to a large preference for enzyme replacement therapy compared with other therapy.

• On the basis of end-user, the market is bifurcated into hospitals and clinics and research and academic institutes. The hospitals and clinics segment accounted for the largest market share in the market and expected to register the fastest growth at a CAGR of 3.1% during the forecast period. The rise in the number of government and private hospitals in emerging countries are the key factors driving the growth of this market.

Regional analysis

The Global Pompe Disease Treatment Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Rest of the World. The Americas are likely to dominate the global Pompe disease treatment market owing to the presence of established payers and an increase in the number of Pompe disease patients in the region. In addition, the presence of a huge number of hospitals in the region also would support the growth of the market during the forecast period. According to a study published by the American Hospital Association in February 2018, there were 5,534 registered hospitals in the US in 2017.

Europe held a substantial share in the global Pompe disease treatment market. This can be attributed to increasing research & development initiatives; and government support for improving the healthcare sector. For instance, European countries are extremely cautious and have implemented the newborn screening (NBS) program as a means of early detection and identification of severe illnesses in newborns.

Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the increasing healthcare expenditure, growing awareness among patients regarding rare disorders, and expanding the healthcare industry in this region.

The Pompe disease treatment market in the Rest of the World is expected to witness steady growth during the review period owing to growing awareness about the treatment of rare diseases and developing healthcare infrastructure.

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Type
2.3.1. Secondary Type
2.3.1.1. Preliminary data mining
2.3.2. Primary Type
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Pompe Disease Market
Chapter 5. Global Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
5.1. Global Pompe Disease Market Share, By Type, 2015 - 2027 (USD Million)
5.1.1. Late-Onset Pompe Disease
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Late-Onset Pompe Disease
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Classic Infantile-Onset Pompe Disease
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Non-Classic Infantile-onset Pompe Disease
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
6.1. Global Nasal Drug Delivery Type Share, By Therapy, 2015 - 2027 (USD Million)
6.1.1. Enzyme Replacement Therapy
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Gene Therapy
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Others
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
7.1. Global Nasal Drug Delivery Type Share, By End User, 2015 - 2027 (USD Million)
7.1.1. Hospitals and Clinics
7.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Research and Academic Institutes
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Pompe Disease Market Overview, By Geography, 2015 – 2027 (USD Million)
8.1. Global Pompe Disease Market Share, By Geography, 2015 - 2027 (USD Million)
8.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 9. Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. Powders Global Pompe Disease Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
9.1.2. Global Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.3. Global Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
9.1.4. Global Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
9.1.5. Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.5.1. U.S. Pompe Disease Market Overview, 2015 - 2027 (USD Million)
9.1.5.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
9.1.5.1.2. U.S. Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.1.3. U.S. Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
9.1.5.1.4. U.S. Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
9.1.5.2. Canada Pompe Disease Market Overview, 2015 - 2027 (USD Million)
9.1.5.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
9.1.5.2.2. Canada Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.2.3. Canada Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
9.1.5.2.4. Canada Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
9.1.5.3. Mexico Pompe Disease Market Overview, 2015 - 2027 (USD Million)
9.1.5.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
9.1.5.3.2. Mexico Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.3.3. Mexico Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
9.1.5.3.4. Mexico Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 10. Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Global Pompe Disease Market Overview, 2015 – 2027 (USD Million)
10.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.2. Global Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.3. Global Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.4. Global Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5. Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.5.1. Germany
10.1.5.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.5.1.2. Germany Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.1.3. Germany Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.1.4. Germany Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.2. France
10.1.5.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.5.2.2. France Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.2.3. France Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.2.4. France Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.3. UK
10.1.5.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.5.3.2. UK Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.3.3. UK Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.3.4. UK Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.4. Italy
10.1.5.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.5.4.2. Italy Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.4.3. Italy Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.4.4. Italy Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.5. Spain
10.1.5.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
10.1.5.5.2. Spain Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.5.3. Spain Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.5.4. Spain Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.6. Rest of Late-Onset Pompe Disease
10.1.5.6.1. Market size and projections, 2015 – 2025
10.1.5.6.2. Rest of Global Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.6.3. Rest of Global Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
10.1.5.6.4. Rest of Global Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 11. Asia Pacific Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Asia Pacific Pompe Disease Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.2. Asia Pacific Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.3. Asia Pacific Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.4. Asia Pacific Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5. Asia Pacific Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.5.1. India
11.1.5.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.5.1.2. India Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.1.3. India Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.5.1.4. India Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.2. China
11.1.5.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.5.2.2. China Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.2.3. China Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.5.2.4. China Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.3. Japan
11.1.5.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.5.3.2. Japan Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.3.3. Japan Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.5.3.4. Japan Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.4. South Korea
11.1.5.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.5.4.2. South Korea Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.4.3. South Korea Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.5.4.4. South Korea Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
11.1.5.5.2. Rest of Asia Pacific Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.5.3. Rest of Asia Pacific Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
11.1.5.5.4. Rest of Asia Pacific Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 12. Middle East & Africa Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Middle East & Africa Pompe Disease Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
12.1.2. Middle East & Africa Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.3. Middle East & Africa Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
12.1.4. Middle East & Africa Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5. Middle East & Africa Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.5.1. GCC
12.1.5.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
12.1.5.1.2. GCC Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.1.3. GCC Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
12.1.5.1.4. GCC Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5.2. South Africa
12.1.5.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
12.1.5.2.2. South Africa Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.2.3. South Africa Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
12.1.5.2.4. South Africa Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
12.1.5.3.2. Rest of Middle East & Africa Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.3.3. Rest of Middle East & Africa Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
12.1.5.3.4. Rest of Middle East & Africa Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 13. South America Global Pompe Disease Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. South America Pompe Disease Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
13.1.2. South America Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.3. South America Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
13.1.4. South America Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5. South America Pompe Disease Market Overview, By Countries, 2015- 2026 (USD Million)
13.1.5.1. Brazil
13.1.5.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
13.1.5.1.2. Brazil Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.1.3. Brazil Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
13.1.5.1.4. Brazil Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5.2. Argentina
13.1.5.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
13.1.5.2.2. Argentina Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.2.3. Argentina Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
13.1.5.2.4. Argentina Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5.3. Rest of South America
13.1.5.3.1. Market size and projections, 2015 – 2026
13.1.5.3.2. Rest of South America Pompe Disease Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.3.3. Rest of South America Pompe Disease Market Overview, By Therapy, 2015 - 2027 (USD Million)
13.1.5.3.4. Rest of South America Pompe Disease Market Overview, By End User, 2015 - 2027 (USD Million)
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2020
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Type & Late-Onset Pompe Disease
Chapter 15. Key Player Analysis
15.1. Amicus Therapeutics (US)
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Type & Late-Onset Pompe Disease Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Sanofi (France)
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Type & Late-Onset Pompe Disease Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. Audentes Therapeutics (US)
15.4. Oxyrane (UK)
15.5. Valerion Therapeutics (US)
15.6. Avrobio, Inc. (US)
15.7. Centogene AG (UK)
Chapter 16. Global Pompe Disease Market Cost Analysis
16.1. Global Pompe Disease Market Key Raw Type Analysis
16.1.1. Key Raw Type
16.1.2. Trend of Key Raw Type
16.1.3. Key Suppliers of Raw Type
16.1.4. Market Concentration Rate of Raw Type
16.2. Proportion of Wing Cost Structure
16.2.1. Raw Type
16.2.2. Labor Cost
16.2.3. Wing Expenses
16.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 17. Chain, Sourcing Strategy and Downstream Buyers
17.1. Global Pompe Disease Market Chain Analysis
17.2. Upstream Raw Type Sourcing
17.3. Raw Type of Global Pompe Disease Market Major Manufacturers in 2019
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Hospitals and Clinics Damage
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Type & Late-Onset Pompe Disease Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Type & Late-Onset Pompe Disease Progress in Related Type
19.2. Late-Onset Pompe Disease Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
 
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Pompe Disease Market share, by Type, 2020 & 2027 (%)
10. Global Pompe Disease Market share, by Late-Onset Pompe Disease, by Type, 2020 & 2027 (USD Million)
11. Global Pompe Disease Market share, by Classic Infantile-Onset Pompe Disease, by Type, 2020 & 2027 (USD Million)
12. Global Pompe Disease Market share, by Non-Classic Infantile-onset Pompe Disease, by Type, 2020 & 2027 (USD Million)
13. Global Pompe Disease Market share, by Therapy, 2020 & 2027 (%)
14. Global Pompe Disease Market share, by Enzyme Replacement Therapy Acid, by Therapy, 2020 & 2027 (USD Million)
15. Global Pompe Disease Market share, by Gene Therapy, by Therapy, 2020 & 2027 (USD Million)
16. Global Pompe Disease Market share, by Others, by Therapy, 2020 & 2027 (USD Million)
17. Global Pompe Disease Market share, by End User, 2020 & 2027 (%)
18. Global Pompe Disease Market share, by Hospitals and Clinics, by End User, 2020 & 2027 (USD Million)
19. Global Pompe Disease Market share, by Research and Academic Institutes, by End User, 2020 & 2027 (USD Million)
20. Global Pompe Disease Market share, by region, 2020 - 2027(%)
21. Global Pompe Disease Market share, by region, 2019 - 2027(USD Million)
22. Powders Global Pompe Disease Market, 2020 - 2027(USD Million)
23. Powders Global Pompe Disease Market share, by Countries, 2020 & 2027 (%)
24. U.S. Global Pompe Disease Market, 2020 - 2027(USD Million)
25. Canada Global Pompe Disease Market, 2020 - 2027(USD Million)
26. Late-Onset Pompe Disease Global Pompe Disease Market, 2020 - 2027(USD Million)
27. Late-Onset Pompe Disease Global Pompe Disease Market share, by Countries, 2020 & 2027 (%)
28. Spain Global Pompe Disease Market, 2020 - 2027(USD Million)
29. UK Global Pompe Disease Market, 2020 - 2027(USD Million)
30. Italy Global Pompe Disease Market, 2020 - 2027(USD Million)
31. Germany Global Pompe Disease Market, 2020 - 2027(USD Million)
32. France Global Pompe Disease Market, 2020 - 2027(USD Million)
33. Rest of Late-Onset Pompe Disease Global Pompe Disease Market, 2020 - 2027(USD Million)
34. Asia-Pacific Global Pompe Disease Market, 2020 - 2027(USD Million)
35. Asia-Pacific Global Pompe Disease Market share, by Countries, 2020 & 2027 (%)
36. China Global Pompe Disease Market, 2020 - 2027(USD Million)
37. India Global Pompe Disease Market, 2020 - 2027(USD Million)
38. Australia Global Pompe Disease Market, 2020 - 2027(USD Million)
39. Japan Global Pompe Disease Market, 2020 - 2027(USD Million)
40. Rest of Asia-Pacific Global Pompe Disease Market, 2020 - 2027(USD Million)
41. Middle East & Africa Global Pompe Disease Market, 2020 - 2027(USD Million)
42. Middle East & Africa Global Pompe Disease Market share, by Countries, 2020 & 2027 (%)
43. GCC Global Pompe Disease Market, 2020 - 2027(USD Million)
44. South Africa Global Pompe Disease Market, 2020 - 2027(USD Million)
45. Rest of Middle East & Africa Global Pompe Disease Market, 2020 - 2027(USD Million)
46. South America Global Pompe Disease Market, 2020 - 2027(USD Million)
47. Brazil Global Pompe Disease Market, 2020 - 2027(USD Million)
48. Mexico Global Pompe Disease Market, 2020 - 2027(USD Million)
49. Argentina Global Pompe Disease Market, 2020 - 2027(USD Million)
50. Rest Of South America Global Pompe Disease Market, 2020 - 2027(USD Million)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Pompe Disease Market, 2020-2027 (USD Million)
4. Global Pompe Disease Market, by country, 2020-2027, (USD Million)
5. North America Pompe Disease Market, By Type, 2020-2027 (USD Million)
6. North America Pompe Disease Market, by Therapy, 2020-2027 (USD Million)
7. North America Pompe Disease Market, by End User, 2020-2027 (USD Million)
8. Europe Pompe Disease Market, By Type, 2020-2027 (USD Million)
9. Europe Pompe Disease Market, by Therapy, 2020-2027 (USD Million)
10. Europe Pompe Disease Market, by End User, 2020-2027 (USD Million)
11. Asia Pacific Pompe Disease Market, By Type, 2020-2027 (USD Million)
12. Asia Pacific Pompe Disease Market, by Therapy, 2020-2027 (USD Million)
13. Asia Pacific Pompe Disease Market, by End User, 2020-2027 (USD Million)
14. Middle East & Africa Global Pompe Disease Market, By Type, 2020-2027 (USD Million)
15. Middle East & Africa Pompe Disease Market, by Therapy, 2020-2027 (USD Million)
16. Middle East & Africa Pompe Disease Market, by End User, 2020-2027 (USD Million)
17. South America Pompe Disease Market, By Type, 2020-2027 (USD Million)
18. South America Pompe Disease Market, by Therapy, 2020-2027 (USD Million)
19. South America Pompe Disease Market, by End User, 2020-2027 (USD Million)
20. Global Pompe Disease Market, Company Market Share, 2018 (%)
21. Amicus Therapeutics (US): Product Benchmarking
22. Amicus Therapeutics (US): Financial Performance
23. Sanofi (France), Product Benchmarking
24. Sanofi (France), Financial Performance
25. Audentes Therapeutics (US) : Product Benchmarking
26. Audentes Therapeutics (US) : Financial Performance
27. Oxyrane (UK): Product Benchmarking
28. Oxyrane (UK): Financial Performance
29. Valerion Therapeutics (US) : Product Benchmarking
30. Valerion Therapeutics (US) : Financial Performance
31. Avrobio, Inc. (US),: Product Benchmarking
32. Avrobio, Inc. (US),: Financial Performance
33. Centogene AG (UK): Product Benchmarking
34. Centogene AG (UK): Financial Performance

The Leading Key Players in Pompe Disease Market

Amicus Therapeutics
Inc (US) Sanofi (France)
Audentes Therapeutics (US)
Oxyrane (UK)
Valerion Therapeutics (US)
AVROBIO Inc. (US)
CENTOGENE AG (UK).

Sample Request Form